Physician profile
Shima Hadidchi
NPI 1780975839
$4,703.47
in general payments reported to CMS, 2019-2025
48 companies · $444 in 2025
The $444 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,162 · 2020: $494 · 2021: $478 · 2022: $669 · 2023: $877 · 2024: $580 · 2025: $444.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,900.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,900.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $689.82 | 2019-2025 | |
| Abbvie INC. | $443.82 | 2021-2025 | |
| Novo Nordisk INC | $426.55 | 2019-2025 | Rybelsus, Ozempic |
| Dexcom, INC. | $383.84 | 2021-2025 | Dexcom G6 Transmitter |
| Amgen INC. | $337.61 | 2019-2025 | Krystexxa, Repatha, Otezla |
| Lilly USA, LLC | $284.66 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $266.17 | 2019-2024 | Airsupra, Breztri, Farxiga |
| Radius Health, INC. | $228.45 | 2019-2021 | |
| Xeris Pharmaceuticals, INC. | $152.47 | 2022-2023 | Gvoke Hypopen |
| Novartis Pharmaceuticals Corporation | $131.51 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $130.22 | 2021-2023 | |
| Allergan, INC. | $105.20 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $101.17 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $95.51 | 2022-2024 | Verquvo, Belsomra |
| Corcept Therapeutics | $73.53 | 2024 | Korlym |
Show all 46 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shima Hadidchi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.